6 completed, 2 terminated, 1 recruiting, 1 unknown. 7 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Recruiting 1, Unknown 1 |
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Light Chain Bioscience - Novimmune SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer Biological NILK-2301 - Colorectal Cancer Metastatic | Phase 1 | Recruiting | Light Chain Bioscience - Novimmune SA | 25 | 2024-04-12 | 2024-10-29 |
| A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers Biological NI-1801, NI-1801 in combination with anti-PD1 (Pembrolizumab), NI-1801 in combination with paclitaxel - Epithelial Ovarian Cancer, Triple Negative Breast Cancer | Phase 1 | Unknown | Light Chain Bioscience - Novimmune SA | 70 | 2022-04-29 | 2024-10-29 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH Emapalumab-Lzsg - Hemophagocytic Lymphohistiocytoses | Phase 2 / Phase 3 | Terminated | Swedish Orphan Biovitrum | 7 | 2020-06-02 | 2023-10-06 |
| Study of an Anti-TLR4 mAb in Rheumatoid Arthritis NI-0101, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Light Chain Bioscience - Novimmune SA | 90 | 2017-05-10 | 2018-08-14 |
| First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers Monoclonal antibody - Healthy Volunteers | Phase 1 | Completed | Light Chain Bioscience - Novimmune SA | 80 | 2012-11-01 | 2014-10-24 |
| NI-0401 in Patients With Acute Renal Allograft Rejection NI-0401 - Acute Renal Transplant Rejection | Phase 1 / Phase 2 | Completed | Light Chain Bioscience - Novimmune SA | 12 | 2007-08-01 | 2009-06-09 |
| NI-0401 in Active Crohn's Disease NI-0401 (anti-CD3 mAB), Placebo - Moderate to Severe Crohn's Disease | Phase 1 / Phase 2 | Completed | Light Chain Bioscience - Novimmune SA | 40 | 2006-01-01 | 2008-03-07 |
| First in Human Study of NI-0701 in Healthy Volunteers NI-0701, Placebo - Healthy Volunteers | Phase 1 | Completed | Light Chain Bioscience - Novimmune SA | 2010-12-07 | ||
| NI-0801 in Allergic Contact Dermatitis Placebo, NI-0801 - Allergic Contact Dermatitis | Phase 1 | Completed | Light Chain Bioscience - Novimmune SA | 22 | 2010-11-19 | |
| Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody NI-0801 - Primary Biliary Cirrhosis | Phase 2 | Terminated | Light Chain Bioscience - Novimmune SA | 2014-04-04 |
Arthritis, Rheumatoid (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Dermatitis, Allergic Contact (1) · Liver Cirrhosis, Biliary (1) · Lymphohistiocytosis, Hemophagocytic (1) · Triple Negative Breast Neoplasms (1)
Antibodies, Monoclonal (1) · Emapalumab (1) · NI-0101 (1) · Paclitaxel (1) · pembrolizumab (1)
France (2) · Italy (2) · United Kingdom (2) · Bosnia and Herzegovina (1) · Bulgaria (1) · Georgia (1) · Hungary (1) · Moldova (1) · Netherlands (1) · Poland (1) · Serbia (1) · Spain (1) · United States (1)
Ernest Choy, MD (1) · J. Koos Prof. Burggraaf, MD, Ph (1) · Janeeke Van der Woude, MD (1) · John Lambert, MD (1) · Radmila Kanceva (1)
2016 (1), 2023 (1)